Chewy vs. Uber Technologies: Which Consumer Stock Is a Better Buy in 2026?

Uber is presented as the stronger long-term choice versus Chewy, supported by FY2025 revenue of about $52 billion (+18%), net income of $10.1 billion, and free cash flow of $9.8 billion. Chewy generated FY2025 revenue of $12.6 billion (+6%), $223 million in net income, and $562 million in free cash flow, while consensus forecasts FY2026 sales growth of 7% and nearly 50% net-income growth to $333 million. Uber's lower leverage (0.4x debt-to-equity versus Chewy's 1.1x), higher margins (19% versus 2%), and perceived competitive moat outweigh concerns that consensus expects its 2026 net income to decline to roughly $6.1 billion despite revenue rising toward $58 billion.

Analysis

The relevant valuation distinction is not P/S but incremental-margin durability. UBER's network density can convert booking growth into higher take rates and lower incentives, while CHWY must fund fulfillment, pricing, and customer acquisition against AMZN and WOOF. UBER's reported earnings should be normalized for equity-value marks and other non-operating items; the cleaner underwriting metric is adjusted EBITDA/FCF per gross booking, not headline net income. That said, a sharp earnings decline in consensus despite revenue growth creates a near-term multiple risk if investment gains normalize or autonomous investments accelerate.

CHWY's upside hinges on mix shift rather than core retail growth. Vet care, pharmacy, and B2B practice relationships could raise gross profit per customer, but clinics introduce fixed occupancy, clinician recruiting, and ramp-loss risk precisely when the legacy retail business has limited room for pricing. The Modern Animal integration is therefore a 6-18 month execution catalyst, not evidence of immediate earnings accretion. A consumer slowdown is also asymmetric: recurring consumables protect revenue, but value-seeking customers can readily price-compare food and litter, leaving gross margin exposed.

Consensus likely overstates UBER's moat if autonomous driving becomes a supplier-cost problem rather than a demand-generation opportunity. Waymo, Tesla, and regional AV fleets could eventually bargain away platform economics in the highest-value urban corridors; conversely, UBER's demand aggregation and dispatch layer may make it the preferred AV distribution partner. Over the next 1-3 months, regulatory developments around contractor classification and booking-growth/incentive trends matter more to the stock than broad mobility demand. CHWY is the cleaner contrarian only if health-services contribution margins and clinic payback are disclosed as improving; without that evidence, its apparent sales multiple discount is deserved.

Key Decisions for Investors

• Prefer a 6-12 month long UBER / short LYFT pair rather than outright UBER: UBER's global scale and delivery cross-sell should sustain relative EBITDA growth, while LYFT remains more exposed to North American fare competition. Reassess if UBER's adjusted EBITDA margin stalls for two consecutive quarters or LYFT materially narrows its incentive gap.
• Do not chase CHWY on a retail-sales multiple. Set an alert for a post-earnings entry only if management shows positive clinic-level contribution margins, stable Autoship customer economics, and no deterioration in retail gross margin; absent those disclosures, maintain neutral-to-underweight versus AMZN.
• For UBER, use downside-defined exposure via 6-9 month call spreads funded by selling an upside call only after confirming the next earnings report separates operating profit from investment gains. Target a 2:1 payoff profile; exit if contractor-classification rulings create a credible employee-model precedent in a major U.S. market.
• Watch WOOF as a read-through on veterinary labor costs and discretionary pet-health demand. Weak WOOF clinic traffic or rising wage pressure would weaken CHWY's health-services margin thesis before it is visible in consolidated results.